Ophthalmic Drugs Conference 2018

SMi Group26 - 27 November 2018, London, UK.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

Building on last year's success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive, half-day post-conference workshops on 28th November 2018, led by twoXAR and Aston University

This Year's Agenda Highlights Include

  • Discover recent advances in the treatment of glaucoma
  • Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
  • Discuss case studies on novel non-invasive and site-specific drug delivery strategies
  • Examine the applications of artificial intelligence in drug discovery
  • Explore use of biomarkers and surrogate end-points from a regulatory perspective

Chairs for 2018

  • Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals
  • Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen

Key Speakers

  • Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
  • Caroline Barelle, CEO, Elasmogen
  • Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
  • Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
  • Aniz Girach, Chief Medical Officer, Nightstar Therapeutics
  • Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
  • David Silverman, Clinical Director, Ophthalmology, Roche

View the full agenda online: www.ophthalmicdrugs.com/wpn

Early-bird rates

  • Register by 29th June and save £300
  • Register by 28th September and save £200
  • Register by 31st October and save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Simple drug combination creates new neurons from n…

A simple drug cocktail that converts cells neighboring damaged neurons into functional new neurons could potentially be used to treat stroke, Alzheimer's disease, and bra...

The Union for International Cancer Control and Pfi…

In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

New insight into cell receptors opens the way for …

New research on how cancer mutations influence a certain type of receptor on the cell membrane opens the way for the development of tailored drugs for certain cancers, su...